Debiopharm and ThinkingNodeLife.ai forge strategic partnership to propel cancer drug development
Lausanne, Switzerland, and San Diego, USA – January 10, 2024. Debiopharm, an independent Swiss biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a U.S.-based AI Digital Cells Lab, announced a strategic collaboration to advance one of Debiopharm's cancer drugs.
A strategic partnership to propel cancer drug development
The collaboration applies TNL's AI Digital Cells Lab, which generates human digital cell clones to predict a drug's effects on human cells and explain its mechanism, to five areas of Debiopharm's program:
- Additional indications: exploring further cancer indications for the drug.
- Combinations: using AI digital knockdowns to identify promising combinations with other drugs in development.
- Mechanism of action: validating how the drug works with mechanistic digital cell clones.
- Comparison: comparing the drug with existing cancer treatments in digital cell clones.
- Biomarkers: discovering predictive biomarkers to guide patient selection.
“We're thrilled to enter this collaboration to advance our oncology drug programs,” said Bertrand Ducrey, CEO of Debiopharm.
“We are excited to start this strategic partnership with Debiopharm,” said Khai Pham, CEO of ThinkingNodeLife.ai.
ThinkingNodeLife.ai is now infinitusbio. This page summarizes the announcement; the full release, with both companies' boilerplates and media contacts, is published by Debiopharm.